12th December 2014
Statement from the The Immunology of Diabetes Society
The Immunology of Diabetes Society (IDS) is a scientific society dedicated to improving understanding and treatment of type 1 diabetes. IDS organizes a Congress every 18 months at which there are scientific presentations to further this goal. IDS entered into an agreement with the conferences division of Elsevier to act as conference organizer for the 14th IDS Congress in Munich in 2015. Subsequently, a controversy has developed over a letter in July in The Lancet, an Elsevier publication, about the situation in Gaza. Regrettably, the controversy is ongoing.
The IDS Council wishes to inform its members that the arrangement with Elsevier to organize the IDS Congress is solely to facilitate the Congress and to increase and disseminate knowledge about the immunology of diabetes. This arrangement should not be interpreted as support for or endorsement of Elsevier’s activities more broadly.
Welcome to the website of The Immunology of Diabetes Society
Much has been discovered about the immunology of type 1 diabetes but more needs to be learned before we reach the goal of treating diabetes without multiple insulin injections each day.
Our Society exists to bring together many strands of scientific endeavor with the goal of better understanding and treatment of type 1 diabetes. These strands include breakdown of tolerance and development of autoimmunity, how beta cells are destroyed by the immune system, the nature of the autoantigens recognized by pathogenic T cells, the role of viruses and other environmental factors in triggering and promoting autoimmunity. We are especially focused on clinical trials of new therapies.
Our scientific congress occurs every 18 months in major centres in Europe, North America and Asia/Oceania. These meetings have been the scene of many breaking discoveries in type 1 diabetes and the scene of many vigorous discussions. I encourage you to make room in your busy calendars for these meetings that are not only highly informative but also a great way to maintain international contacts and networks amongst type 1 diabetes colleagues.
Professor Thomas Kay